Latest Drugwonks' Blog
Rumors are flying.
If true, what will this mean for Michael Moore's favorite health care system?
If true, what will this mean for Michael Moore's favorite health care system?
From the London Times...
From The TimesAugust 24, 2007
Britain the worst for deaths from strokes
Nigel Hawkes, Health Editor
"Patients who suffer strokes receive worse treatment in Britain than anywhere else in Western Europe .
More die and more are left disabled, a leading expert says in this week’s British Medical Journal, even though Britain spends as much as, if not more than, other countries on stroke care. "
On the bright side...the NHS has reduced waiting times for access to explosive belts down to zero.
Meanwhile liberals -- mostly in the form of The New Republic's Jonathan Cohn -- are wandering the globe in search of a health care system better than ours. They first went to Canada, then the VA, then the UK, then France, only to find or omitting real problems. Leave it to the Commonwealth Fund to remain steadfast in supporting the idea of shoving everyone into Medicaid or Medicare.
And as we speak the SCHIP proposal is tanking because -- strangely -- the idea of stealing Medicare money from poor seniors to pay for Medicaid for rich kids is not flying.
I can't wait for the health care debate in 2008.
From The TimesAugust 24, 2007
Britain the worst for deaths from strokes
Nigel Hawkes, Health Editor
"Patients who suffer strokes receive worse treatment in Britain than anywhere else in Western Europe .
More die and more are left disabled, a leading expert says in this week’s British Medical Journal, even though Britain spends as much as, if not more than, other countries on stroke care. "
On the bright side...the NHS has reduced waiting times for access to explosive belts down to zero.
Meanwhile liberals -- mostly in the form of The New Republic's Jonathan Cohn -- are wandering the globe in search of a health care system better than ours. They first went to Canada, then the VA, then the UK, then France, only to find or omitting real problems. Leave it to the Commonwealth Fund to remain steadfast in supporting the idea of shoving everyone into Medicaid or Medicare.
And as we speak the SCHIP proposal is tanking because -- strangely -- the idea of stealing Medicare money from poor seniors to pay for Medicaid for rich kids is not flying.
I can't wait for the health care debate in 2008.
0 Comments
Yesterday I had the privilege to attend and participate in the third annual FDA Regulatory & Compliance Symposium held at Harvard University. (Or as we Martlets call it, "The McGill University of the South.)
My panel focused on federal preemption and DTC advertising issues. The title of my presentation was "FDA: Advancing the Public Health or Being Led by Political Whims." Needless to say, it was hard to limit my remarks to the requisite 45 minutes.
Two of the other panelists were Alex Sugerman-Brozan (of the Prescription Access Litigation Project) and Lauren Guth Barnes of the law firm Hagens Berman Sobol Shapiro. Perhaps the most polite way to put it is that we didn't agree on most issues.
And that's okay. A feisty, robust -- and respectful debate is always worthwhile. And this panel was certainly all of those things.
Of the many differences, I'm sure you can fill in the blanks vis-Ã -vis our divergent views on both federal preemption and DTC issues. But what I found most disturbing was that both Alex and Lauren relied, almost exclusively, on partial research data, one-sided anecdotes, and rather selective legal citations.
Their presentations were as one-sided as they were narrow and they lacked any perspective as to the unintended consequences of (what I viewed as) simplistic alternatives. They spoke of solutions driven by adjudication and legislation -- with nary a nod to science.
(Although we did find some common ground on the need for better and more disease awareness advertising and the banishment of reminder ads.)
But (and here's the good news) while their ideas are wrong -- their hearts are in the right place. I really believe that. I hope that, with more conversation (both face-to-face and otherwise) we can all work to help advance the public health through a strong and better funded FDA.
My panel focused on federal preemption and DTC advertising issues. The title of my presentation was "FDA: Advancing the Public Health or Being Led by Political Whims." Needless to say, it was hard to limit my remarks to the requisite 45 minutes.
Two of the other panelists were Alex Sugerman-Brozan (of the Prescription Access Litigation Project) and Lauren Guth Barnes of the law firm Hagens Berman Sobol Shapiro. Perhaps the most polite way to put it is that we didn't agree on most issues.
And that's okay. A feisty, robust -- and respectful debate is always worthwhile. And this panel was certainly all of those things.
Of the many differences, I'm sure you can fill in the blanks vis-Ã -vis our divergent views on both federal preemption and DTC issues. But what I found most disturbing was that both Alex and Lauren relied, almost exclusively, on partial research data, one-sided anecdotes, and rather selective legal citations.
Their presentations were as one-sided as they were narrow and they lacked any perspective as to the unintended consequences of (what I viewed as) simplistic alternatives. They spoke of solutions driven by adjudication and legislation -- with nary a nod to science.
(Although we did find some common ground on the need for better and more disease awareness advertising and the banishment of reminder ads.)
But (and here's the good news) while their ideas are wrong -- their hearts are in the right place. I really believe that. I hope that, with more conversation (both face-to-face and otherwise) we can all work to help advance the public health through a strong and better funded FDA.
0 Comments
In Win for Drug Manufacturers, 3rd Circuit Rules Only FDA Can Regulate Ads
Shannon P. Duffy
The Legal Intelligencer
In a big win for drug manufacturers, the 3rd U.S. Circuit Court of Appeals has ruled that federal law bars a suit alleging false-advertising claims under state law because the U.S. Food and Drug Administration has "exclusive authority" to regulate prescription drug advertising.
"To allow generalized state consumer fraud laws to dictate the parameters of false and misleading advertising in the prescription drug context would pose an undue obstacle to both Congress' and the FDA's objectives in protecting the nation's prescription drug users," U.S. Circuit Judge D. Brooks Smith of the Western District of Pennsylvania, wrote in his 51-page opinion in Pennsylvania Employees Benefit Trust Fund, et al. v. Zeneca Inc.
But a dissenting judge complained that such "implied conflict pre-emption" of state law was unwarranted and wrong since the FDA doesn't have the power to require preapproval of pharmaceutical advertisements and lacks the resources to police the ads that run after drugs are approved.
Senior U.S. Circuit Judge Robert E. Cowen said he would have revived the suit because the claims it alleges don't challenge any of the drug maker's claims before the FDA during its labeling process, and therefore posed no conflict with the FDA's mission.
"Given that there are limitations to the FDA's oversight over prescription drug advertisements -- both congressionally imposed limitations, such as the lack of authority to require preapproval, and practical limitations attendant to the sheer volume of drug advertisements in the media, the supplementation of state-law remedies would seem to aid the FDCA's objectives and purposes, not frustrate them," Cowen wrote.
The ruling upholds the dismissal of a proposed class action suit accusing Zeneca of misleading consumers and doctors by advertising the acid reflux drug Nexium as an improvement over Prilosec because it knew that the patent for Prilosec was about to expire and a generic version would soon be hitting the market.
The suit, filed in U.S. District Court in Delaware, alleged claims under the Delaware Consumer Fraud Act as well as the consumer protection statutes of the 50 states for false, misleading and deceptive advertising. It also alleged claims for unjust enrichment and negligent misrepresentation.
Nexium and Prilosec are both proton-pump inhibitors -- drugs that treat gastroesophageal reflux disease, or GERD, and erosive esophagitis, conditions that are commonly known as acid reflux disease and frequent heartburn.
Prilosec was an especially profitable drug for Zeneca, with sales of more than $6 billion in 2000. But the patent for Prilosec was due to expire in 2001, at which point it would be available for sale as the generic drug omeprazole.
In February 2001, Zeneca obtained final approval from the FDA for its labeling on Nexium, the brand name for esomeprazole magnesium.
A clinical study of Nexium compared both 20 mg and 40 mg doses of Nexium with the approved 20 mg dose of Prilosec and showed that 40 mg of Nexium had a statistically significant healing rate over 20 mg of Prilosec.
But the suit alleged that the higher dose of Nexium was not needed for most patients, and that Zeneca's ad campaign was therefore misleading because a fair comparison of 20 mg of Nexium with 20 mg of Prilosec would not have proven Nexium to be superior.
The suit also alleged that Zeneca initially sold Nexium at a price below Prilosec in order to establish brand loyalty, but "then raised the price of Nexium while the price of Prilosec dropped." Nexium now sells for more than $4 per pill versus about 67 cents for Prilosec, the suit alleged.
But U.S. District Judge Sue L. Robinson dismissed the suit, finding that since the Nexium advertisements complied with the FDA-approved labeling, they were not actionable under the state consumer protection laws.
Robinson concluded that the suit was pre-empted because the state law claims conflicted with federal law.
On appeal, plaintiffs lawyers argued that Robinson's application of federal pre-emption was incorrect because there is no irreconcilable conflict between the state consumer fraud laws and the federal Food, Drug and Cosmetic Act. The FDA's approval of Nexium's labeling, they argued, did not extend to an assertion of Nexium's superiority over Prilosec.
Smith disagreed, finding that Robinson's analysis was correct because the FDCA and its implementing regulations include extensive rules governing pharmaceutical advertising. "The degree of discretion inherent in the regulations demonstrates that the FDA envisioned itself occupying an ongoing and extensive role in the supervision of prescription drug advertising,"
Smith wrote in an opinion joined by visiting 6th Circuit Judge Eugene E. Siler. In the claims against Zeneca under state consumer fraud laws, Smith said, the FDCA is not a "critical element" because the plaintiffs wouldn't have to show noncompliance with the FDCA to prevail.
Nonetheless, Smith said, "allowing these claims to proceed would unnecessarily frustrate the FDCA's purpose and FDA regulations, as the extent of agency involvement in regulating prescription drug advertising is extensive and specific."
Implied conflict pre-emption of the state consumer fraud laws was therefore required, Smith said, because both the FDCA and FDA regulations provide specific requirements for prescription drug advertising.
"The high level of specificity in federal law and regulations with respect to prescription drug advertising is irreconcilable with general state laws that purport to govern all types of advertising," Smith wrote.
In dissent, Cowen complained that his colleagues were ignoring the teachings of U.S. Supreme Court decisions that cautioned against "seeking out conflicts between state and federal regulation where none clearly exists."
Cowen said courts must "start with the assumption that the historic police powers of the states were not to be superseded by [a] federal act unless that was the clear and manifest purpose of Congress."
Although the FDA has exclusive power to approve the sale and labeling of drugs, Cowen argued that the agency does not have the exclusive power to regulate drug advertising. "This is not an area of the law inherently requiring national uniformity and ousting all related state law," Cowen wrote.
In the suit against Zeneca, Cowen said, the plaintiffs are complaining that ads for Nexium contained a false and misleading drug comparison -- an issue that was never addressed by the FDA in its approval of Nexium's labeling.
"As a result, there is no risk that a successful state-law claim, alleging that Nexium advertisements contain false and misleading drug comparisons, would conflict with the FDA's approval of the statements in the Nexium labeling," Cowen wrote.
Lead plaintiffs attorney Craig R. Spiegel of Hagens Berman Sobol Shapiro in Seattle could not be reached for comment.
Zeneca was represented in the appeal by Mark E. Haddad of the Los Angeles office of Sidley Austin, along with Jack B. Blumenfeld, Rudolph J. Scaggs Jr. and Lisa K. Whittaker of Morris Nichols Arsht & Tunnell in Wilmington, Del.
Shannon P. Duffy
The Legal Intelligencer
In a big win for drug manufacturers, the 3rd U.S. Circuit Court of Appeals has ruled that federal law bars a suit alleging false-advertising claims under state law because the U.S. Food and Drug Administration has "exclusive authority" to regulate prescription drug advertising.
"To allow generalized state consumer fraud laws to dictate the parameters of false and misleading advertising in the prescription drug context would pose an undue obstacle to both Congress' and the FDA's objectives in protecting the nation's prescription drug users," U.S. Circuit Judge D. Brooks Smith of the Western District of Pennsylvania, wrote in his 51-page opinion in Pennsylvania Employees Benefit Trust Fund, et al. v. Zeneca Inc.
But a dissenting judge complained that such "implied conflict pre-emption" of state law was unwarranted and wrong since the FDA doesn't have the power to require preapproval of pharmaceutical advertisements and lacks the resources to police the ads that run after drugs are approved.
Senior U.S. Circuit Judge Robert E. Cowen said he would have revived the suit because the claims it alleges don't challenge any of the drug maker's claims before the FDA during its labeling process, and therefore posed no conflict with the FDA's mission.
"Given that there are limitations to the FDA's oversight over prescription drug advertisements -- both congressionally imposed limitations, such as the lack of authority to require preapproval, and practical limitations attendant to the sheer volume of drug advertisements in the media, the supplementation of state-law remedies would seem to aid the FDCA's objectives and purposes, not frustrate them," Cowen wrote.
The ruling upholds the dismissal of a proposed class action suit accusing Zeneca of misleading consumers and doctors by advertising the acid reflux drug Nexium as an improvement over Prilosec because it knew that the patent for Prilosec was about to expire and a generic version would soon be hitting the market.
The suit, filed in U.S. District Court in Delaware, alleged claims under the Delaware Consumer Fraud Act as well as the consumer protection statutes of the 50 states for false, misleading and deceptive advertising. It also alleged claims for unjust enrichment and negligent misrepresentation.
Nexium and Prilosec are both proton-pump inhibitors -- drugs that treat gastroesophageal reflux disease, or GERD, and erosive esophagitis, conditions that are commonly known as acid reflux disease and frequent heartburn.
Prilosec was an especially profitable drug for Zeneca, with sales of more than $6 billion in 2000. But the patent for Prilosec was due to expire in 2001, at which point it would be available for sale as the generic drug omeprazole.
In February 2001, Zeneca obtained final approval from the FDA for its labeling on Nexium, the brand name for esomeprazole magnesium.
A clinical study of Nexium compared both 20 mg and 40 mg doses of Nexium with the approved 20 mg dose of Prilosec and showed that 40 mg of Nexium had a statistically significant healing rate over 20 mg of Prilosec.
But the suit alleged that the higher dose of Nexium was not needed for most patients, and that Zeneca's ad campaign was therefore misleading because a fair comparison of 20 mg of Nexium with 20 mg of Prilosec would not have proven Nexium to be superior.
The suit also alleged that Zeneca initially sold Nexium at a price below Prilosec in order to establish brand loyalty, but "then raised the price of Nexium while the price of Prilosec dropped." Nexium now sells for more than $4 per pill versus about 67 cents for Prilosec, the suit alleged.
But U.S. District Judge Sue L. Robinson dismissed the suit, finding that since the Nexium advertisements complied with the FDA-approved labeling, they were not actionable under the state consumer protection laws.
Robinson concluded that the suit was pre-empted because the state law claims conflicted with federal law.
On appeal, plaintiffs lawyers argued that Robinson's application of federal pre-emption was incorrect because there is no irreconcilable conflict between the state consumer fraud laws and the federal Food, Drug and Cosmetic Act. The FDA's approval of Nexium's labeling, they argued, did not extend to an assertion of Nexium's superiority over Prilosec.
Smith disagreed, finding that Robinson's analysis was correct because the FDCA and its implementing regulations include extensive rules governing pharmaceutical advertising. "The degree of discretion inherent in the regulations demonstrates that the FDA envisioned itself occupying an ongoing and extensive role in the supervision of prescription drug advertising,"
Smith wrote in an opinion joined by visiting 6th Circuit Judge Eugene E. Siler. In the claims against Zeneca under state consumer fraud laws, Smith said, the FDCA is not a "critical element" because the plaintiffs wouldn't have to show noncompliance with the FDCA to prevail.
Nonetheless, Smith said, "allowing these claims to proceed would unnecessarily frustrate the FDCA's purpose and FDA regulations, as the extent of agency involvement in regulating prescription drug advertising is extensive and specific."
Implied conflict pre-emption of the state consumer fraud laws was therefore required, Smith said, because both the FDCA and FDA regulations provide specific requirements for prescription drug advertising.
"The high level of specificity in federal law and regulations with respect to prescription drug advertising is irreconcilable with general state laws that purport to govern all types of advertising," Smith wrote.
In dissent, Cowen complained that his colleagues were ignoring the teachings of U.S. Supreme Court decisions that cautioned against "seeking out conflicts between state and federal regulation where none clearly exists."
Cowen said courts must "start with the assumption that the historic police powers of the states were not to be superseded by [a] federal act unless that was the clear and manifest purpose of Congress."
Although the FDA has exclusive power to approve the sale and labeling of drugs, Cowen argued that the agency does not have the exclusive power to regulate drug advertising. "This is not an area of the law inherently requiring national uniformity and ousting all related state law," Cowen wrote.
In the suit against Zeneca, Cowen said, the plaintiffs are complaining that ads for Nexium contained a false and misleading drug comparison -- an issue that was never addressed by the FDA in its approval of Nexium's labeling.
"As a result, there is no risk that a successful state-law claim, alleging that Nexium advertisements contain false and misleading drug comparisons, would conflict with the FDA's approval of the statements in the Nexium labeling," Cowen wrote.
Lead plaintiffs attorney Craig R. Spiegel of Hagens Berman Sobol Shapiro in Seattle could not be reached for comment.
Zeneca was represented in the appeal by Mark E. Haddad of the Los Angeles office of Sidley Austin, along with Jack B. Blumenfeld, Rudolph J. Scaggs Jr. and Lisa K. Whittaker of Morris Nichols Arsht & Tunnell in Wilmington, Del.
0 Comments
What a great use of FDA user fees:
"Federal regulators plan to study whether relaxing, upbeat images featured in TV drug ads distract consumers from warnings about the drugs' risks.
The announcement, posted Tuesday to the Food and Drug Administration's Web site, comes a week after a study published in the New England Journal of Medicine suggested the agency's drug-ad enforcement has steadily declined.
The FDA says it plans to study how 2,000 people react to television drug ads to determine whether they have an overwhelmingly positive impression of products despite audio warnings about potential side effects."
Matt Perrone of the AP zeroes in on my favorites...the Cialis ad which "features a middle-aged couple returning from a shopping trip while smooth jazz plays in the background. Toward the ad's end, a male voice lists common side effects, including headache, back pain and muscle aches." Note that the FDA put the kibosh on a female voice in ED drug ads...The agency found a female voice too....stimulating.
Leave it to the longest running joke in the so-called consumer movement, Sid Wolfe, to come up with what he thinks is a serious proposal but could be a great idea for a late night comedy sketch:
"If advertisers were really interested in getting information about drug risks out, they'd show pictures of those problems, but you almost never see that," said Dr. Sidney Wolfe of the advocacy group Public Citizen, which frequently criticizes drug industry marketing.
Yeah, I could see that. A couple in a hot tub about to engage in Clinton-like behavior only to have Sid Wolfe pop up from underneath the steamy H20 to begin reciting all the side effects.
Sid Wolfe in a hot tub droning on about drug safety. Now that's a good use of FDA user fees.
http://www.businessweek.com/ap/financialnews/D8R5I8900.htm
"Federal regulators plan to study whether relaxing, upbeat images featured in TV drug ads distract consumers from warnings about the drugs' risks.
The announcement, posted Tuesday to the Food and Drug Administration's Web site, comes a week after a study published in the New England Journal of Medicine suggested the agency's drug-ad enforcement has steadily declined.
The FDA says it plans to study how 2,000 people react to television drug ads to determine whether they have an overwhelmingly positive impression of products despite audio warnings about potential side effects."
Matt Perrone of the AP zeroes in on my favorites...the Cialis ad which "features a middle-aged couple returning from a shopping trip while smooth jazz plays in the background. Toward the ad's end, a male voice lists common side effects, including headache, back pain and muscle aches." Note that the FDA put the kibosh on a female voice in ED drug ads...The agency found a female voice too....stimulating.
Leave it to the longest running joke in the so-called consumer movement, Sid Wolfe, to come up with what he thinks is a serious proposal but could be a great idea for a late night comedy sketch:
"If advertisers were really interested in getting information about drug risks out, they'd show pictures of those problems, but you almost never see that," said Dr. Sidney Wolfe of the advocacy group Public Citizen, which frequently criticizes drug industry marketing.
Yeah, I could see that. A couple in a hot tub about to engage in Clinton-like behavior only to have Sid Wolfe pop up from underneath the steamy H20 to begin reciting all the side effects.
Sid Wolfe in a hot tub droning on about drug safety. Now that's a good use of FDA user fees.
http://www.businessweek.com/ap/financialnews/D8R5I8900.htm
0 Comments
I am a big believer in FDA-approved generic drugs. They are safe and effective and represent an enormous opportunity for health care savings -- and I applaud insurance company programs that seek to educate consumers about them. But I am a big opponent of forced switching. Disempowering physicians and patients results in bad outcomes.
I am a big believer in getting the right medicine to the right patient in the right dose at the right time. But I am a big opponent of the Me-Tooistas, who think that all drugs within the same therapeutic category are, more-or-less, the same.
I believe in honesty and ethical behavior, and I have strong feelings when it comes to the topic of insurance companies not being transparent about providing financial incentives to physicians in order to influence their prescribing habits -- while misleading patients along the way.
Sometimes the best of intentions have serious unintended consequences.
Consider the Blue Care Network of Michigan (BCN). A program (now discontinued) sent letters out to their participating primary care physicians offering a $100 payment “for each member in their panel with a BCN pharmacy benefit who fills a prescription for a generic lipid lowering agent.â€
Translation: We will pay you $100 for switching your patients to a generic statin.
According to a recent ABC investigative report, “Blue Care Network in Michigan paid 2,400 doctors $2 million to switch their patients from Lipitor to a generic version of its competitor, Zocor. They were paid $100 for each patient they switched from Jan. 1 through March 31, 2007.â€
Translation Update: We will pay you $100 to switch your patient to a generic statin that isn't even a generic version of what they are currently taking.
When asked by the ABC reporter if patients knew their doctors were receiving payments from the insurance company in return for a service that helps to increase the profits of the insurance company, the response from BCN was “not specifically.â€
Translation: No.
What ever happened to informed consent?
Here’s what BCN wrote to their customers being prescribed Lipitor:
“Our prescription claim records indicate you may be taking Lipitor® for high cholesterol. Another lipid lowering drug, Simvastatin, works as well as Lipitor® but is available as a generic and costs a lot less.â€
Please note – the preceding paragraph is a verbatim quote from the BCN letter.
A few comments:
* As to “ … as well as …â€, imagine if a pharmaceutical company tried to pull that one? They’d be hit by a DDMAC truck as fast as you can say, well, DDMAC.
Talk about an unlevel playing field.
* Seems to me (maybe it’s just me) that somebody's trying to make it sound like Simvastatin is a generic version of Lipitor. “… works as well as Lipitor® but is available as a generic …†You be the judge.
“Not specifically†seems to be more than an evasive answer to a journalist's question – it appears to also be a creative viewpoint on bioequivalence -- a flawed and dangerous one. Honestly folks, how will the average consumer read and understand such verbiage? It’s also interesting to note that nowhere in the consumer letter does it mention that doctors will be spiffed for making the switch.
Imagine if a pharmaceutical company engaged in such behavior? Can you say OIG investigation? Big fine? Congressional investigation?
Lastly (and by no means least), where are the medical guidelines on the best ways to monitor a patient (particularly an already stabilized one) being switched from one statin to another (specifically, from one molecule to another)?
Maybe the $100 payment paid for some CME on that count.
Or maybe, well, “not specifically.â€
Transparency please.
I am a big believer in getting the right medicine to the right patient in the right dose at the right time. But I am a big opponent of the Me-Tooistas, who think that all drugs within the same therapeutic category are, more-or-less, the same.
I believe in honesty and ethical behavior, and I have strong feelings when it comes to the topic of insurance companies not being transparent about providing financial incentives to physicians in order to influence their prescribing habits -- while misleading patients along the way.
Sometimes the best of intentions have serious unintended consequences.
Consider the Blue Care Network of Michigan (BCN). A program (now discontinued) sent letters out to their participating primary care physicians offering a $100 payment “for each member in their panel with a BCN pharmacy benefit who fills a prescription for a generic lipid lowering agent.â€
Translation: We will pay you $100 for switching your patients to a generic statin.
According to a recent ABC investigative report, “Blue Care Network in Michigan paid 2,400 doctors $2 million to switch their patients from Lipitor to a generic version of its competitor, Zocor. They were paid $100 for each patient they switched from Jan. 1 through March 31, 2007.â€
Translation Update: We will pay you $100 to switch your patient to a generic statin that isn't even a generic version of what they are currently taking.
When asked by the ABC reporter if patients knew their doctors were receiving payments from the insurance company in return for a service that helps to increase the profits of the insurance company, the response from BCN was “not specifically.â€
Translation: No.
What ever happened to informed consent?
Here’s what BCN wrote to their customers being prescribed Lipitor:
“Our prescription claim records indicate you may be taking Lipitor® for high cholesterol. Another lipid lowering drug, Simvastatin, works as well as Lipitor® but is available as a generic and costs a lot less.â€
Please note – the preceding paragraph is a verbatim quote from the BCN letter.
A few comments:
* As to “ … as well as …â€, imagine if a pharmaceutical company tried to pull that one? They’d be hit by a DDMAC truck as fast as you can say, well, DDMAC.
Talk about an unlevel playing field.
* Seems to me (maybe it’s just me) that somebody's trying to make it sound like Simvastatin is a generic version of Lipitor. “… works as well as Lipitor® but is available as a generic …†You be the judge.
“Not specifically†seems to be more than an evasive answer to a journalist's question – it appears to also be a creative viewpoint on bioequivalence -- a flawed and dangerous one. Honestly folks, how will the average consumer read and understand such verbiage? It’s also interesting to note that nowhere in the consumer letter does it mention that doctors will be spiffed for making the switch.
Imagine if a pharmaceutical company engaged in such behavior? Can you say OIG investigation? Big fine? Congressional investigation?
Lastly (and by no means least), where are the medical guidelines on the best ways to monitor a patient (particularly an already stabilized one) being switched from one statin to another (specifically, from one molecule to another)?
Maybe the $100 payment paid for some CME on that count.
Or maybe, well, “not specifically.â€
Transparency please.
0 Comments
My oped on how Arnold Relman is pleading with Canadians not to escape single payer purgatory.
http://washingtontimes.com/apps/pbcs.dll/article?AID=/20070821/EDITORIAL/108210009/1013/editorial&template=nextpage
http://washingtontimes.com/apps/pbcs.dll/article?AID=/20070821/EDITORIAL/108210009/1013/editorial&template=nextpage
This from the AFP
Cancer Survival Rate Up in Europe
"Cancer survival has improved across Europe, with eastern European nations beginning to close the gap with western neighbours, according to a study covering the decade up to 2002, released Tuesday.
The study, published in the British journal The Lancet, showed a clear link between high rates of survival and the amount spent on health, but pointed out that Britain lagged well behind other countries with similar national health budgets.
An accompanying editorial in the influential journal called for a "fundamental reassessment" of Britain's cancer policy in light of the fact that survival rates were comparable to eastern European countries that spent two-thirds less.
"So has the cancer plan worked? The short answer is seemingly no," it concluded, suggesting that the National Health Service should be "divorced from political control and short-term political gains."
http://news.yahoo.com/s/afp/20070821/ts_afp/healthcancereurope
Oh you mean the effort to place health care budgets under the wise and experienced direction of bureaucrats seeking to bring costs under control by limiting access to drugs in the political spotlight is killing patients? The most the NHS spends the less it gets for its dollars.
As in NICE which is hailed as the gold standard of comparative effectiveness and cost effectiveness evaluation by the folks at AHIP, Commonwealth Fund, HealthDespairs, Medpac and now at CMS.
Our government -- in the form of the FDA and now at CMS -- is at war against cancer patients. It is a direct result of the policies pursued by those whose politics are shaped by unchecked hatred against the companies that make medicines. They are supported by a fawning media, by nuts on the net, and financially by trial attorneys. They are killing patients and crippling their lives. Well done.
Cancer Survival Rate Up in Europe
"Cancer survival has improved across Europe, with eastern European nations beginning to close the gap with western neighbours, according to a study covering the decade up to 2002, released Tuesday.
The study, published in the British journal The Lancet, showed a clear link between high rates of survival and the amount spent on health, but pointed out that Britain lagged well behind other countries with similar national health budgets.
An accompanying editorial in the influential journal called for a "fundamental reassessment" of Britain's cancer policy in light of the fact that survival rates were comparable to eastern European countries that spent two-thirds less.
"So has the cancer plan worked? The short answer is seemingly no," it concluded, suggesting that the National Health Service should be "divorced from political control and short-term political gains."
http://news.yahoo.com/s/afp/20070821/ts_afp/healthcancereurope
Oh you mean the effort to place health care budgets under the wise and experienced direction of bureaucrats seeking to bring costs under control by limiting access to drugs in the political spotlight is killing patients? The most the NHS spends the less it gets for its dollars.
As in NICE which is hailed as the gold standard of comparative effectiveness and cost effectiveness evaluation by the folks at AHIP, Commonwealth Fund, HealthDespairs, Medpac and now at CMS.
Our government -- in the form of the FDA and now at CMS -- is at war against cancer patients. It is a direct result of the policies pursued by those whose politics are shaped by unchecked hatred against the companies that make medicines. They are supported by a fawning media, by nuts on the net, and financially by trial attorneys. They are killing patients and crippling their lives. Well done.
0 Comments
Sex is prime cause of China's HIV
By Jill McGivering
BBC News
Activists are pushing China to change the way it tackles HIV. China's state media says unsafe sex has, for the first time, become the main means of transmission of HIV/Aids, overtaking intravenous drug use.
http://news.bbc.co.uk/2hi/asia-pacific/6954859.stm
Attention must be paid.
By Jill McGivering
BBC News
Activists are pushing China to change the way it tackles HIV. China's state media says unsafe sex has, for the first time, become the main means of transmission of HIV/Aids, overtaking intravenous drug use.
http://news.bbc.co.uk/2hi/asia-pacific/6954859.stm
Attention must be paid.
0 Comments
Would the National Federation of Independent Businesses support legislation that would restrict the right of it's members to decide which distributors to sell or ship products to at what price or make it a federal crime to refuse to do business with a particular company because they were re-selling your products from China into America at below market price that hurt your bottom line? That's unconstitutional, right?
Well it has by destroyed one of the pillars of capitalism by supporting the Pharmaceutical Market Access and Drug Safety Act of 2007 which contains such provisions.
Shame on the NFIB for selling out. I hope it was worth it.
Well it has by destroyed one of the pillars of capitalism by supporting the Pharmaceutical Market Access and Drug Safety Act of 2007 which contains such provisions.
Shame on the NFIB for selling out. I hope it was worth it.
Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.
